Association of ANCA-associated vasculitis-rheumatoid arthritis overlap syndrome in four patients: Rituximab may be the right choice?

References

• Pai S, Panda M. Limited Wegener's granulomatosis presenting as lung nodules in a patient with rheumatoid arthritis: a case report. Cases J. 2008; 1 1: 417.
   Google Scholar
• Pritchard MH. Wegener's granulomatosis presenting as theumatoid arthritis (two cases). Proc R Soc Med. 1976; 69 7: 501–504.
   Google Scholar
• Svirskii AA, Potapenkov MA, Shchipulin PP, Kharitonov VM, Zelenin VS. [Wegener's granulomatosis in a patient with rheumatoid arthritis]. Lik Sprava. 19942: 92–94.
   Google Scholar
• Ohashi H, Itoh M, Ogawa N, Sudo Y, Endo S, Okugawa T, . Wegener's granulomatosis in a patient with a rheumatoid arthritis. Intern Med. 1992; 31 9: 1128–1131.
   Google Scholar
• Sturrock RD, Ratnesar P. Wegener's granulomatosis occurring in a patient with pre-existing rheumatoid arthritis. Br J Clin Pract. 1974; 28 5: 183–184.
   Google Scholar
• Chinoy H, McKenna F. Wegener's granulomatosis and rheumatoid arthritis overlap. Rheumatology (Oxford). 2002; 41 5: 588–589.
   Google Scholar
• Douglas G, Bird K, Flume P, Silver R, Bolster M. Wegener's granulomatosis in patients with rheumatoid arthritis. J Rheumatol. 2003; 30 9: 2064–2069.
   Google Scholar
• Palomar R, Castaneda O, Rodrigo E, Ruiz San-Millan JC, Martin Gago J, Morales P, . [Microscopic polyangiitis in a patient with rheumatoid arthritis]. Nefrologia. 2005; 25 4: 438–441.
   Google Scholar
• Ortiz-Santamaria V, Serra A, Teixido J, Olive A. [Rheumatoid arthritis associated with microscopic polyangiitis]. Med Clin (Barc). 2000; 114 20: 793–794.
   Google Scholar
• Soubrier M, Le Seaux S, Dubost JJ, Mizony MH, Ristori JM, Bussiere JL. [Rheumatoid arthritis preceding microscopic polyangitis. Report of two cases]. Rev Med Intern. 2000; 21 1: 78–82.
   Google Scholar
• Steuer A, Palmer A, Colaco CB. A patient with rheumatoid arthritis and microscopic polyarteritis. Br J Rheumatol. 1995; 34 12: 1185–1186.
   Google Scholar
• Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, . The American College of Rheumatology criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990; 33 8: 1101–1107.
   PubMed Web of Science ®Google Scholar
• Yorioka N, Taniguchi Y, Amimoto D, Miyata H, Yamakido M, Taguchi T. Chronic rheumatoid arthritis complicated by myeloperoxidase antineutrophil cytoplasmic antibody-associated nephritis. Am J Nephrol. 1999; 19 4: 527–529.
   Google Scholar
• Goto A, Mukai M, Notoya A, Kohno M. Rheumatoid arthritis complicated with myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis: a case report. Mod Rheumatol. 2005; 15 2: 118–122.
   PubMedGoogle Scholar
• Mustila A, Korpela M, Mustonen J, Helin H, Huhtala H, Soppi E, . Perinuclearantineutrophil cytoplasmic antibody in rheumatoid arthritis: a marker of severe disease with associated nephropathy. Arthritis Rheum. 1997; 40 4: 710–717.
   Google Scholar
• Mustila A, Paimela L, Leirisalo-Repo M, Huhtala H, Miettinen A. Antineutrophil cytoplasmic antibodies in patients with early rheumatoid arthritis: an early marker of progressive erosive disease. Arthritis Rheum. 2000; 43 6: 1371–1377.
   Google Scholar
• Tur BS, Suldur N, Ataman S, Tutkak H, Atay MB, Duzgun N. Anti-neutrophil cytoplasmic antibodies in patients with rheumatoid arthritis: clinical, biological, and radiological correlations. Joint Bone Spine. 2004; 71 3: 198–202.
   Google Scholar
• Bosch X, Llena J, Collado A, Font J, Mirapeix E, Ingelmo M, . Occurrence of antineutrophil cytoplasmic and antineutrophil (peri)nuclear antibodies in rheumatoid arthritis. J Rheumatol. 1995; 22 11: 2038–2045.
   Google Scholar
• Jagiello P, Aries P, Arning L, Wagenleiter SE, Csernok E, Hellmich B, . The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum. 2005; 52 12: 4039–4043.
   Google Scholar
• Farago B, Talian GC, Komlosi K, Nagy G, Berki T, Gyetvai A, . Protein tyrosine phosphatase gene C1858T allele confers risk for rheumatoid arthritis in Hungarian subjects. Rheumatol Int. 2009; 29 7: 793–796.
   Google Scholar
• Johansson M, Arlestig L, Hallmans G, Rantapaa-Dahlqvist S. PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Res Ther. 2006; 8 1: R19.
   Web of Science ®Google Scholar
• Lee AT, Li W, Liew A, Bombardier C, Weisman M, Massarotti EM, . The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status. Genes Immun. 2005; 6 2: 129–133.
   Google Scholar
• Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, . Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2007; 66 2: 143–150.
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, . The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006; 54 5: 1390–1400.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, . Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010; 363 3: 221–232.
   PubMed Web of Science ®Google Scholar
• Watts RA. Vasculitis syndromes: Inducing remission in ANCA-positive vasculitis: time to RAVE?. Nat Rev Rheumatol. 2010; 6 3: 127–128.
   Google Scholar
• Falk RJ, Jennette JC. Rituximab in ANCA-associated disease. N Engl J Med. 2010; 363 3: 285–286.
   Google Scholar
• Gomez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X. B-cell depleting agents for ANCA vasculitides: A new therapeutic approach. Autoimmun Rev Nov 21 (Epub). 2011.
   Google Scholar
• Fervenza FC. Rituximab in ANCA-Associated Vasculitis: Fad or Fact?. Nephron Clin Pract. 2010; 118 2: c182–c1c8.
   Google Scholar
• Hinze CH, Colbert RA. B-cell depletion in Wegener's granulomatosis. Clin Rev Allergy Immunol. 2008; 34 3: 372–379.
   Web of Science ®Google Scholar
• Chen M, Kallenberg CG. ANCA-associated vasculitides–advances in pathogenesis and treatment. Nat Rev Rheumatol. 2010; 6 11: 653–664.
   PubMed Web of Science ®Google Scholar
• Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant. 2011; 26:2865–2871.
   PubMed Web of Science ®Google Scholar
• Niles J. Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis. Clin ExpImmunol 164 Suppl1:27–30.
   Google Scholar